Citigroup Initiates Coverage On Olema Pharmaceuticals with Buy Rating, Announces Price Target of $20

Olema Pharmaceuticals, Inc. +1.86%

Olema Pharmaceuticals, Inc.




Citigroup analyst Yigal Nochomovitz initiates coverage on Olema Pharmaceuticals (NASDAQ: OLMA) with a Buy rating and announces Price Target of $20.
Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via